<--- Back to Details
First PageDocument Content
Medicine / Health / Euphoriants / Controlled Substances Act / Diversion Investigator / Pharmaceuticals policy / Drug diversion / Comprehensive Drug Abuse Prevention and Control Act / Controlled substance / Drug Enforcement Administration / Drug control law / Drug policy
Date: 2014-04-05 13:23:49
Medicine
Health
Euphoriants
Controlled Substances Act
Diversion Investigator
Pharmaceuticals policy
Drug diversion
Comprehensive Drug Abuse Prevention and Control Act
Controlled substance
Drug Enforcement Administration
Drug control law
Drug policy

Microsoft Word - ControlledSubst01.doc

Add to Reading List

Source URL: docs.house.gov

Download Document from Source Website

File Size: 84,83 KB

Share Document on Facebook

Similar Documents

FINECURE PHARMACEUTICALS LIMITED NOMINATION AND REMUNERATION POLICY I. PREAMBLE

DocID: 1vhvU - View Document

For over 20 years, Health Policy Associates has been providing practical and highly efficient consulting solutions to companies involved in developing new medical device technologies, pharmaceuticals and biologics. Clin

DocID: 1vdpM - View Document

FINECURE PHARMACEUTICALS LIMITED POLICY ON ARCHIVAL OF DOCUMENTS 1. PREAMBLE The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR") came into force fr

DocID: 1v1UD - View Document

FINECURE PHARMACEUTICALS LTD. CIN: U24230GJ2005PLC045724 CORPORATE SOCIAL RESPONSIBILITY POLICY Registered Office:

DocID: 1uqeg - View Document

Privacy Policy Revised as of April 4, 2018 Welcome to www.minivelle.com, a web site owned by Noven Pharmaceuticals, Inc. (Noven, our, or we). This Privacy Policy is designed to tell you about our practices regarding coll

DocID: 1un1u - View Document